eligibility_summary
Eligible: Histologically confirmed esophageal squamous cell carcinoma after 2-4 cycles of induction chemo(immunotherapy) with stable/locoregionally progressive or surgeon-assessed unresectable disease (no distant mets), KPS ≥70, adequate labs: Hb ≥100 g/L, ANC ≥1.5x10^9/L, PLT ≥100x10^9/L, WBC ≥3.5x10^9/L, ALT/AST, TBIL ≤1.5xULN, Cr ≤1.5xULN, BUN ≤ULN. Exclude: other malignancies (except cured skin BCC, cervical CIS), distant mets, active TB/hepatitis, contraindications to targeted therapy.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
NCT06410651: single-arm phase II trial in unresectable, locally advanced esophageal squamous cell carcinoma after failed induction therapy, testing nimotuzumab plus concurrent S‑1 chemoradiotherapy (40–50.4 Gy), with surgery as feasible. Nimotuzumab is a humanized anti‑EGFR monoclonal antibody (biologic) that blocks ligand binding, inhibits EGFR signaling (RAS/RAF/MEK/ERK, PI3K/AKT), suppresses proliferation, enhances radiosensitivity, and can induce ADCC via NK cells. S‑1 is an oral fluoropyrimidine (tegafur/gimeracil/oteracil) delivering 5‑FU, it inhibits thymidylate synthase and incorporates into RNA/DNA, killing rapidly dividing cells and radiosensitizing tumors. Radiotherapy causes DNA double‑strand breaks. Targets: EGFR‑overexpressing ESCC cells, downstream mitogenic/survival pathways, thymidylate synthase–dependent DNA synthesis, radiation‑induced DNA damage response, immune effector engagement via ADCC.